Association of preoperative serum IGF- I concentration with clinicopathological parameters in patients with non-small cell lung cancer

Abstract

Insulin-like growth factor-I (IGF-I) is a mitogenic and anti-apoptotic factor. Serum IGF-I concentration is related to some cancer risk and tumor progression. The aim of this research was to study the association of preoperative serum IGF-I concentration with clinicopathological parameters and prognosis of non-small cell lung cancer (NSCLC). Preoperative serum IGF-I concentration was measured in 80 consecutive patients with NSCLC who underwent radical lung cancer resection, and 45 patients with benign pulmonary lesion (BPL) by using enzyme linked immunosorbent assay (ELISA). The results showed that the serum IGF-I concentration was elevated and correlated with clinicopathological parameters and overall survival (OS) in NSCLC patients. Serum IGF-I concentration was significantly higher in patients with NSCLC than in those with BPL. The IGF-I concentrations were significantly higher in NSCLC patients with ≥T2, N1-3, and in IIIA-IV but not in those with <T2, N0, or IA-IIB. The increased serum IGF-I concentration was significantly correlated with poor prognosis. Our data show the positive correlation between IGF-I serum concentration and the tumor size for the first time. It seems that IGF-I related to the progression of lung cancer may depend on autocrine/paracrine function. In addition, our study reveals that higher serum IGF-I concentration is correlated with larger tumor size, advanced stages, local lymph node metastasis and worse prognosis, indicating that endocrine IGF-I is also important for the progression for NSCLC.

Keywords

non-small cell lung cancer / insulin-like growth factor I / enzyme linked immunosorbent assay / prognosis

References

[1] SohdaM, KatoH, MiyazakiT, et al.. The role of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in human esophageal cancer. Anticancer Res, 2004, 24(5A): 3029-3034

[2] MiyataY, SakaiH, HayashiT, et al.. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate, 2003, 54(2): 125-132

[3] ShersherDD, VercilloMS, FhiedC, et al.. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg, 2011, 92(5): 1805-1811

[4] VlachostergiosPJ, GioulbasanisI, KamposiorasK, et al.. Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients. Oncology, 2011, 81(2): 113-118

[5] GrimbergA, CohenP. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol, 2000, 183(1): 1-9

[6] LakshmikuttyammaA, PasturalE, TakahashiN, et al.. Bcr-Abl induces autocrine IGF-1 signaling. Oncogene, 2008, 27(27): 3831-3844

[7] von WichertG, HaeusslerU, GretenFR, et al.. Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells. Oncogene, 2005, 24(7): 1284-1289

[8] Del MonteP, LaurinoC, ArvigoM, et al.. Effects of alpha-interferon on insulin-like growth factor-I, insulin-like growth factor-II and insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in vitro. J Endocrinol Invest, 2005, 28(5): 432-439

[9] MinutoF, Del MonteP, BarrecaA, et al.. Evidence for autocrine mitogenic stimulation by somatomedin-C/ insulin-like growth factor I on an established human lung cancer cell line. Cancer Res, 1988, 48(13): 3716-3719

[10] YuH, SpitzMR, MistryJ, et al.. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst, 1999, 91(2): 151-156

[11] LukanovaA, TonioloP, AkhmedkhanovA, et al.. A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. Int J Cancer, 2001, 92(6): 888-892

[12] GualbertoA, PollakM. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets, 2009, 10(10): 923-936

[13] ChunKH, KosmederJW2nd, SunS, et al.. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst, 2003, 95(4): 291-302

[14] LiaoYD, ZhouS, ZhaoJP, et al.. Expression and significance of IGF1, IGF1R and AKT, the components of IGF signaling pathway, in primary adenocarcinoma of the lung. Shiyong Zhongliuxue Zazhi (Chinese), 2006, 21(1): 15-19

[15] LiaoYD, ZhaoJP, ZhouS, et al.. The correlation between IGF1, IGF2 expression and lymph node metastasis in non-small cell lung cancer. Zhongliu Fangzhi Yanjiu (Chinese), 2006, 33(12): 868-871

[16] LiaoYD, LongQH, ZhouS, et al.. Expression and prognostic significance of insulin-like growth factor 1 in non-small cell lung cancer. Zhongguo Anzheng Zazhi (Chinese), 2005, 15(4): 321-325